Showing 2716 results
-
Press Release /The digital press release with multimedia content can be accessed here: Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of…
-
Press Release /Felix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt…
-
Press Release /Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,…
-
Ad-hoc Releases /Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
-
Press Release /Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
-
Press Release /Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
-
Press Release /European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Ad-hoc Releases /If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
-
Press Release /Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (…
-
Ad-hoc Releases /Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)…